Hyperprolactinemia Clinical Trial
Official title:
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
Treatment of prolactin secreting pituitary tumors with traditional ergot dopamine agonist drugs can be limited by medication side effects, pharmacologic resistance, and by concerns regarding the potential risk of cardiac valve disease. The overall goal of this project is therefore to evaluate, for the first time, the efficacy and tolerability of the selective D2/D3 receptor non-ergot dopamine agonist ropinirole for the treatment of prolactinomas. This proposal will establish the pharmacologic profile of this medication when used to treat hyperprolactinemia in patients with prolactinomas and will determine the impact of long-term ropinirole administration on critical clinical parameters including serum prolactin levels, gonadal function, and tumor regression, in order to establish ropinirole's utility as a new, clinically efficacious, safer and more tolerable therapeutic option for the treatment of prolactinomas that may prove particularly useful in patients with underlying cardiac valve disease and in those with resistance or intolerance to ergot dopamine agonists. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03569787 -
Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire
|
||
Completed |
NCT02098668 -
Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
|
N/A | |
Not yet recruiting |
NCT00541554 -
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
|
Phase 4 | |
Completed |
NCT01270711 -
Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
|
N/A | |
Completed |
NCT02956447 -
Administration of Kisspeptin in Patients With Hyperprolactinemia
|
Phase 2 | |
Recruiting |
NCT05033119 -
PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics
|
||
Completed |
NCT06326840 -
Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment
|
N/A | |
Withdrawn |
NCT00699530 -
Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment
|
N/A | |
Not yet recruiting |
NCT00315081 -
Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine
|
Phase 3 | |
Recruiting |
NCT04746313 -
Prevalence of Hyperprolactinemia in Systemic Scleroderma
|
||
Terminated |
NCT04146389 -
Hyperprolactinemia and Adrenal Steroidogenesis
|
||
Recruiting |
NCT00914823 -
Kisspeptin Administration in the Adult
|
Phase 1 | |
Suspended |
NCT02603549 -
Pituitary Function and Spontaneous Intracranial Hypotension
|
||
Completed |
NCT01852331 -
Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia
|
Phase 2 | |
Completed |
NCT01338298 -
Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
|
N/A | |
Completed |
NCT01052948 -
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
|
N/A | |
Completed |
NCT00436111 -
Characterization of Macroprolactinemia
|
N/A | |
Active, not recruiting |
NCT04439747 -
Develop and Implement Methods for Diagnostic and Treatment of Hormonal Disorders in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT01742390 -
A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders
|
Phase 4 | |
Completed |
NCT00625950 -
Endometriosis Patients Undergoing Quinagolide Treatment
|
Phase 4 |